Reports Q4 revenue $62.5M, consensus $61.87M. “During the fourth quarter, we improved upon the mid-single digit case volume growth that we experienced in the third quarter. This was driven by increasing demand for our comprehensive suite of 3D bunion correction systems by our growing base of over 3,300 surgeon customers,” said John T. Treace, CEO and Chairman of Treace. “In 2026, we expect our expanded bunion portfolio and forthcoming product launches to deliver continued market share gains and restore topline growth in the back half of the year.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical to highlight new product innovations, present data at ACFAS
- Treace Medical Issues Preliminary Q4 Results, Highlights Growth
- Treace Medical sees Q4 revenue $62.1M-$62.5M, consensus $61.76M
- Treace Medical anticipates ‘continued positive procedure volume growth’
- Treace Medical reports completion of first Lapiplasty Lightning technology case